Chronic subcutaneous injection of rotenone produces rodent Parkinsonian models

Chinese Pharmacological Bulletin

Volumn 21, Issue 10, 2005, Pages 1274-1277

  Zhao, Xi Lin ^a   Gu, Zhen Lun ^a   Qin, Zheng Hong ^a  

^a NONE

Author keywords

Parkinsons disease; Rotenone; Substantia nigra; Tyrosine hydroxylase; synuclein

Indexed keywords

ALPHA SYNUCLEIN; ROTENONE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INCLUSION; CELL LOSS; CHRONIC DRUG ADMINISTRATION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MORTALITY; NERVE CELL; NISSL STAINING; NONHUMAN; PARKINSONISM; PROTEIN AGGREGATION; RAT; RODENT; SUBSTANTIA NIGRA; TREMOR;

EID: 29144437116     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Betarbet R, Sherer TB, Mackenzie et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease[J]. Nat Neurosci, 2000, 3 (12): 1301-6.
2. Ferrante RJ, Schulz JB, Kowall NW et al. Systemic administration of rotenone produces selective damage in striatum and globus pallidus, but not in the substantia nigra[J]. Brain Res, 1997, 753 (1): 157-62.
3. Fang N, Rowlands JC, Casida JE et al. Anomalors structure-activity relationships of 13-homo-13-oxarotenoids and 13-homo-13-oxadehy drorotenoids[J]. Chem Res Toxicol, 1997, 10 (8): 853-8.
4. Hollingworth RM, Ahammadsahib KI, Gadelak G et al. New inhibitors of complex I of the mitochondrial electron transport chain with activity as pesticide[J]. Biochem Soc Trans, 1994, 22 (1): 230-3.
5. RFriedrich T, Ohnishi T, Forche E et al. Two binding site for naturally occurring inhibitor in mitochondrial and bacterial NADH: ubiquinone oxidoreductase (complex I) [J]. Biochem Soc Trans, 1994, 22 (1): 226-30.
6. Li N, Ragheb K, Lawler G et al. Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production[J]. Biological Chemistry, 2003, 278 (10): 8516-25.
7. He Y, Imam SZ, Dong Z et al. Role of nitric oxide in rotenone-induced nigro-striatal injury[J]. Neurochemistry, 2003, 86 (6): 1338-45.
8. Gao HM, Liu B, Hong JS. Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons [J]. Neurosci, 2003; 23 (15): 6181-7.
9. Ling Z, Chang QA, Tong CW et al. Rotenone potentiates dopamine neuron loss in animals exposed to lipopolysaccharide prenatally [J]. Exp Neurol, 2004, 190 (2): 373-83.
10. Zhu C, Vourch P, Fernagut PO et al. Variable effects of chronic subcutaneous administration of rotenone on striatal histology[J]. Comp Neurol, 2004, 478 (4): 418-26.
11. M Alam, WJ Schmidt. L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats[J]. Behav Brain Res, 2004, 153 (2): 439-46.
12. Sherer TB, Betarbet R, Testa CM et al. Mechanism of toxicity in rotenone models of Parkinson's disease[J]. Neurosci, 2003, 23 (34): 10756-64.
13. Sherer TB, Kim JH, Betarbet R et al. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and α-synuclein aggregation[J]. Experimental Neurology, 2003, 179: 9-16.